Synapse - Breast Medicine Service

Results (4181)

Racial and socioeconomic disparities in cardiotoxicity among women with HER2-positive breast cancer

Journal Article

Al-Sadawi, M.; Hussain, Y.; Copeland-Halperin, R. S.; Tobin, J. N.; Moskowitz, C. S.; Dang, C. T.; Liu, J. E.; Steingart, R. M.; Johnson, M. N.; Yu, A. F.
American Journal of Cardiology (2021)

Fulltext@MSK | Save

Health-related quality of life (HRQOL) outcomes in arandomized controlled trial of yoga in breast and gynecological cancer survivors with chemotherapy-induced peripheral neuropathy

Meeting Abstract

Zhi, W. I.; Baser, R.; Zhi, L.; Piulson, L.; Li, Q.; Bao, T.
Cancer Research (2021)

Fulltext@MSK | Save

Identification of proteomics-based biomarkers for ER+/HER2- breast cancer stratification: Implications on clinical outcome

Meeting Abstract

Wang, G.; Shah, P.; Searfoss, R.; Campbell, J. L. F.; Hooke, J. A.; Deyarmin, B.; Zingmark, R. N.; Somiari, S.; Liu, J.; Kvecher, L.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results

Meeting Abstract

Rugo, H. S.; Lerebours, F.; Juric, D.; Turner, N.; Chia, S.; Drullinsky, P.; Prat, A.; Vázquez, R. V.; Akdere, M.; Arce, C.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer

Meeting Abstract

Traina, T. A.; Cobain, E. F.; Evron, E.; Duksin, C.; Gordon, G.
Cancer Research (2021)

Fulltext@MSK | Save

Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)

Meeting Abstract

Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

Meeting Abstract

O'Shaughnessy, J.; Schwartzberg, L.; Piccart, M.; Rugo, H. S.; Yardley, D. A.; Cortes, J.; Untch, M.; Harbeck, N.; Wright, G. S.; Bondarenko, I.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer

Meeting Abstract

Park, K. U.; Gregory, M. E.; Lustberg, M. B.; Bazan, J. G.; Shen, C.; Rosenberg, S. M.; Blinder, V. S.; Sharma, P.; Pusztai, L.; Partridge, A. H.; more...
Cancer Research (2021)

Fulltext@MSK | Save

A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)

Meeting Abstract

Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
Cancer Research (2021)

Fulltext@MSK | Save